{"id":59895,"date":"2026-03-19T13:59:36","date_gmt":"2026-03-19T05:59:36","guid":{"rendered":"https:\/\/flcube.com\/?p=59895"},"modified":"2026-03-19T13:59:37","modified_gmt":"2026-03-19T05:59:37","slug":"fda-releases-draft-guidance-on-nams-accelerating-shift-from-animal-testing-to-human-relevant-drug-safety-assessment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59895","title":{"rendered":"FDA Releases Draft Guidance on NAMs \u2013 Accelerating Shift from Animal Testing to Human\u2011Relevant Drug Safety Assessment"},"content":{"rendered":"\n

The US Food and Drug Administration (FDA)<\/strong> has advanced its “Roadmap to Reducing Animal Testing in Preclinical Safety Studies”<\/strong> with the release of Draft Guidance on Alternatives to Animal Testing in Drug Development<\/strong>, establishing a regulatory framework for New Approach Methodologies (NAMs)<\/strong> to replace traditional animal models with human\u2011relevant data in drug safety qualification.<\/p>\n\n\n\n

Regulatory Development<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>US Food and Drug Administration (FDA)<\/td><\/tr>
Initiative<\/strong><\/td>Roadmap to Reducing Animal Testing in Preclinical Safety Studies<\/td><\/tr>
Document<\/strong><\/td>Draft Guidance on Alternatives to Animal Testing in Drug Development<\/td><\/tr>
Issuing Center<\/strong><\/td>Center for Drug Evaluation and Research (CDER)<\/td><\/tr>
Scope<\/strong><\/td>Qualification of NAMs for IND\/NDA\/BLA submissions and OTC drug monograph orders (Section 505G, FD&C Act)<\/td><\/tr>
Strategic Goal<\/strong><\/td>Accelerate safe and effective drug availability through human\u2011relevant data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

NAMs Qualification Framework \u2013 Four Key Areas<\/h2>\n\n\n\n
Pillar<\/th>Requirement<\/th>Regulatory Intent<\/th><\/tr><\/thead>
1. Context of Use (COU)<\/strong><\/td>Clearly define proposed regulatory use of NAM<\/td>Establishes specific application scope for each methodology<\/td><\/tr>
2. Human Biological Relevance<\/strong><\/td>Demonstrate effective assessment of human toxicity<\/td>Ensures translational validity vs. interspecies extrapolation limitations<\/td><\/tr>
3. Technical Characterization<\/strong><\/td>Robust, reliable, reproducible methods<\/td>Scientific confidence through method validation and standardization<\/td><\/tr>
4. Fit\u2011for\u2011Purpose<\/strong><\/td>Suitability for informing regulatory decisions<\/td>Alignment with drug review and approval process requirements<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Scientific & Strategic Rationale<\/h2>\n\n\n\n